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Alcohol, smoking and other substance use in the perinatal period  
 
Many women use substances during pregnancy. For example, global prevalence of alcohol 
use during pregnancy is 9.8%.1 Moreover, 10.4% of pregnant women in England were 
known to be smoking tobacco at the time of delivery2 and prevalence of cannabis use during 
pregnancy in a UK cohort has previously been reported as 5%3 but is likely to increase over 
coming years.4 Pregnancy may be a woman’s first time engaging with health services and 
may be a motivator to stop or reduce her substance use.5 Yet many clinicians feel ill 
equipped to advise women on their substance use during this period. In this article we offer 
an overview of assessment and interventions for substance use in the perinatal period. We 
focus on alcohol, tobacco and cannabis use, as these are more commonly encountered by 
the generalist clinician6; we focus less on the more complex population engaging in 
polysubstance use.  
Exploring substance use in pregnancy 
The World Health Organisation recommend healthcare providers ask all pregnant women 
about substance use (past and present) as early as possible in pregnancy and at every 
antenatal visit.7 When asked about substance use, the woman may feel able unable to 
disclose this as she may feel judged or worry that her parenting ability will be questioned. 
Therefore such enquiry is best done by a professional who the woman trusts and with 
whom she has established a rapport, preferably in the preconception period.8 Suggestions 
for what to ask in the consultation are listed in Box 1. Such questions may include type and 
quantity of substances used and impact on daily life, which is important to consider when 
evaluating risk.  
What you need to know 
• Ask about substance use in all women who are pregnant or planning pregnancy.   
• Early brief interventions may be effective when delivered by non-specialists in 
the primary care setting. 
• Support for women who use substances during pregnancy may involve liaison 
with other services such as midwifery and specialist drug and alcohol services.  
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Ask about symptoms of anxiety and depression9 and physical ill health. Consider the broader 
stressors occurring alongside substance use; are there others in the family or household 
who are also using substances? Be aware that substance use can be associated with 
violence, abuse and exploitation.10 Such histories in which there are high levels of social, 
medical and psychological morbidity and polysubstance use may raise safeguarding 
concerns about risk for the mother, her unborn infant and wider family.11 Always explain 
conditions under which you may have to breach confidentiality;12 if you need to make a 
safeguarding referral discuss this with the woman beforehand whenever possible and 
provide ongoing support.  
Managing substance use in pregnancy 
Develop and agree a management plan in collaboration with the woman, based on a risk-
benefit discussion informed by up-to-date evidence. The plan will differ with the type and 
level of substances used and local availability of services.  
Offer brief interventions early in pregnancy for women seeking to reduce or stop their 
substance use.7 Brief interventions are short, structured interventions to encourage 
behaviour change and Box 2 provides suggestions of questions to ask;13 this includes enquiry 
by the clinician about current level of use and discussion with the woman about the 
potential risks of substance use and support available.  
In primary care there is moderate quality evidence that brief intervention in harmful or 
hazardous drinkers can reduce alcohol consumption by around a pint of beer (475 ml) or a 
third of a bottle of wine (250 ml) each week.14 There is evidence for the effectiveness  of 
interventions as brief as giving a patient information leaflet.15 However, there is less 
evidence to support the use of brief interventions for other substances16 and limited 
understanding of how this may translate to women in pregnancy.  
Following brief intervention, further contact with the woman may be required; this provides 
an opportunity to develop a relationship and further explore substance use. It is also allows 
women who are initially ambivalent about change to consider the information that you have 
given them at the initial contact,17 although it is also important to emphasise the 
importance of stopping or reducing use as early in pregnancy as possible. Liaise with 
midwifery, who can also help in signposting to services such as smoking cessation and who 
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sometimes have a specialist midwife for substance misuse. If more extended interventions 
are required, referral to other services may be necessary. Women who may benefit from 
referral to specialist drug and alcohol services are those who are dependent on substances 
such as alcohol and opioids18 (Box 3), who require substitute prescribing or who have 
complex comorbidities. A range of psychosocial interventions are available in specialist drug 
and alcohol services.19 These women may also benefit from perinatal psychiatry services if 
they are available.   
UK Department of Health guidelines encourage breastfeeding, even in women who continue 
to misuse substances, except in those using cocaine or crack cocaine or high doses of 
benzodiazepines.20 Aim to discuss breastfeeding intentions as early in pregnancy as possible, 
individualising the risk-benefit discussion to the specific substance use profile. 
Alcohol  
There is no known safe alcohol consumption level in pregnancy so a conversation with a 
woman who is worried that she has drunk alcohol in early pregnancy can be challenging. 
Heavy drinking and binge drinking (≥8 units for men or ≥6 units for women on one occasion) 
in pregnancy is associated with an increased risk of prematurity and low birth weight21 22 
and a range of physical, behavioural and learning problems, collectively known as Fetal 
Alcohol Spectrum Disorders. Neonates may also experience a withdrawal syndrome. 
However, it is important to emphasise that this is a dose-response relationship23 and that 
the association between lower levels of consumption (<4 units per week) and adverse 
outcomes is less clear.24 Nonetheless, current advice from UK and Australian Departments 
of Health and US Centres for Disease Control and Prevention (CDC) is to abstain completely 
from alcohol in pregnancy.19 25 26  
Support pregnant women using alcohol to ideally stop or if not, reduce their alcohol 
consumption.20 There are a number of screening tools for use in the non-pregnant 
population, such as the three question AUDIT-C,27 although there is limited evidence for its 
validity during pregnancy.28 29  
For women dependent on alcohol, refer to a service that can support early detoxification,7 
ideally as an inpatient, with chlordiazepoxide as per usual protocol.30 Advise against 
stopping drinking suddenly due to life-threatening complications of alcohol withdrawal, 
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such as seizures. There are insufficient data on safety to support use of relapse prevention 
medication such as acamprosate, disulfiram and naltrexone in pregnancy.30 However, clearly 
risks of relapse versus maintaining abstinence need to be weighed for each woman.  
Tobacco 
Smoking during pregnancy is associated with a range of adverse offspring outcomes, 
including reduced fetal growth.31 It is also associated with an increased risk of miscarriage, 
prematurity, placental abruption and still birth.31 Provide information about magnitude of 
risk; for example in 2018 there were four stillbirths per total 1000 births in England and 
Wales.32 Risk of stillbirth is estimated to increase by 47% in women who smoke during 
pregnancy,33 increasing this risk to almost six in 1000. A dose-response relationship has also 
been observed; the risk is increased by 9% in women who smoke nine or fewer cigarettes 
per day versus 52% in women who smoke ten or more.33 
Offer referral to all pregnant women currently smoking or who have stopped in the last two 
weeks to specialist smoking cessation services.34 There is moderate to high quality 
systematic review evidence that psychosocial interventions improve rates of smoking 
cessation (by 35%) and subsequently reduce rates of low birth weight (by 17%).35 NHS 
England advise that carbon monoxide testing be offered at antenatal booking and as 
required throughout pregnancy to identify women exposed to tobacco.36 This may be 
conducted within a similar framework to the brief intervention discussed above known as 
‘Ask (smoking status), Advise (results of carbon monoxide screening), Act (refer to smoking 
cessation services)’.37 Consider alternatives which are likely to be safer than cigarettes, such 
as nicotine replacement therapy (NRT), within the context of an informed discussion with 
the woman.37 38 Bupropion or varenicline are not indicated for smoking cessation in 
pregnant or breastfeeding women.30  
Cannabis  
Tetrahydrocannabinol (THC): the major psychoactive component of cannabis, readily 
crosses the placental barrier.39 Synthetic cannabinoid receptor agonists (SCRAs), e.g. ‘Spice’, 
are also potent stimulators of the endocannabinoid system and their safety during 
pregnancy is unknown. Some observational studies have found an association between 
cannabis and a range of adverse obstetric and neonatal outcomes and longer-term adverse 
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child neurobehavioral outcomes but others have failed to observe such an association.40-43 
Given this uncertainty,, encourage women using cannabis in pregnancy to achieve complete 
abstinence.30 44 Be aware of the potential for cannabis, when smoked with tobacco, to 
potentiate adverse effects of both substances.45 
Quantify how much cannabis is being used and consider a brief intervention in less heavy 
users but offer referral to specialist drug and alcohol services for heavy users, where more 
intensive psychosocial interventions may be offered. The questions in Box 1 can help in 
distinguishing these groups of women for whom cannabis may play a lesser or greater role 
in their lives.   
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Case scenario 
Clare is a 30 year old primip who is delighted to find herself pregnant. She comes to your 
surgery for confirmation of the pregnancy. You discover that she is smoking 20 cigarettes 
per day and she is worried that she went to a friend’s wedding around the time of 
conception and drank so much she couldn’t remember what had happened until the 
next day. She also reports occasional recreational use of cannabis.  
Next steps: 
Advise Clare of the risks of smoking and alcohol and cannabis use during pregnancy. The 
biggest risk for Clare at present is her smoking. 
Offer referral to specialist pregnancy smoking cessation clinic. 
Clarify with Clare how much cannabis and alcohol she is using. Brief intervention may be 
sufficient but if heavier use of either substance, referral to specialist drug and alcohol 
service may be indicated. 
 
 
How patients were involved in the creation of this article 
One of the article’s authors: CK, has lived experience of the topic. She was consulted 
throughout the article’s production, including its conceptualisation and during the 
writing process, when she stressed the importance of asking all women about their 
substance use during pregnancy. She also emphasised the value of professionals 
discussing referrals to children’s social care with the woman prior to the referral being 
made.  
 
Education into practice 
 How do you ask women attending your practice t  report their preg ancy about their 
substance use? W at training has your practice nurse received on givi g smoking 
cessation advice to pregna t women?How any of your pregnant wom n are smokers 
and what proportion have b en offered smoking cessation adv ce? 
 
Useful resources for clinicians 
Royal College of Paediatrics and Child Health safeguarding learning resources for 
professionals: https://www.rcpch.ac.uk/resources/safeguarding-learning-
resources 
 
Smoking cessation: a briefing for midwifery staff: 
https://www.ncsct.co.uk/usr/pub/Midwifery_briefing_%20V3.pdf 
 
Patient infographic on electronic cigarettes in pregnancy: 
http://smokefreeaction.org.uk/wp-content/uploads/2017/06/SIPe-cig-
infographic.pdf 
 
Royal College of Obstetricians and Gynaecologists alcohol and pregnancy patient 
information leaflet: https://www.rcog.org.uk/en/patients/patient-
leaflets/alcohol-and-pregnancy/ 
 
Current guidelines: 
UK Department of Health. Drug misuse and dependence: UK guidelines on clinical 
management (2017). 
Available from: https://www.gov.uk/government/publications/drug-misuse-and-
dependence-uk-guidelines-on-clinical-management  
 
British Association for Psychopharmacology (BAP). Consensus guidance on the 
use of psychotropic medication preconception, in pregnancy and postpartum 
(2017).  
Available from: https://www.bap.org.uk/pdfs/BAP_Guidelines-Perinatal.pdf    
 
World Health Organisation (WHO). Guidelines for the identification and 
management of substance use and substance use disorders in pregnancy (2014). 
Available from: 
http://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/ 
 
British Association for Psychopharmacology (BAP). Evidence-based guidelines for 
the pharmacological management of substance abuse, harmful use, addiction 
and comorbidity (2012).  
Available from: https://www.bap.org.uk/pdfs/BAP_Guidelines-Addiction.pdf    
 
UK National Institute for Health and Care Excellence (NICE). Clinical guideline 
(CG192)- Antenatal and postnatal mental health: clinical management and 
service guidance (2018).  
Available from: https://www.nice.org.uk/guidance/CG192  
 
UK National Institute for Health and Care Excellence (NICE). Clinical guideline 
(CG110)- Pregnancy and complex social factors: a model for service provision for 
pregnant women with complex social factors (2010).  
Available from: https://www.nice.org.uk/Guidance/CG110 
 
UK National Institute for Health and Care Excellence (NICE). Public health 
guidance 26- How to stop smoking in pregnancy and following childbirth (2010).  
Available from: https://www.nice.org.uk/guidance/PH26 
 
Commented [WC38]: Tom, in the box above, you changed 
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How patients were involved in the creation of this article 
CK has lived experience of the topic. She was consulted throughout the article’s 
production, including its conceptualisation and during the writing process, when she 
stressed the importance of asking all women about their substance use during 
pregnancy. She also emphasised the value of professionals discussing referrals to 
children’s social care with the woman prior to the referral being made.  
 
Case scenario 
Clare is a 30 year old primip who is delighted to find herself pregnant. She comes to your 
surgery for confirmation of the pregnancy. You discover that she is smoking 20 cigarettes 
per day and she is worried that she went to a friend’s wedding around the time of 
conception and drank so much she couldn’t remember what had happened until the 
next day. She also reports occasional recreational use of cannabis.  
Next steps: 
Advise Clare of the risks of smoking and alcohol and cannabis use during pregnancy. The 
biggest risk for Clare at present is her smoking. 
Offer referral to specialist pregnancy smoking cessation clinic. 
Clarify with Clare how much cannabis and alcohol she is using. Brief intervention may be 
sufficient but if heavier use of either substance, referral to specialist drug and alcohol 
service may be indicated. 
 
 
Education into practice 
How do you ask women attending your practice to report their pregnancy about their 
substance use?  
What training has your practice nurse received on giving smoking cessation advice to 
pregnant women? 
How many of your pregnant women are smokers and what proportion have been 
offered smoking cessation advice? 
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Box 1- Questions to consider asking about substance use during pregnancy or in women 
planning a pregnancy 
• Ask permission: Is it ok if I ask you some questions about substance use that can 
affect pregnancy? 
• Use third person: Health professionals are encouraged to ask all women in 
pregnancy about substance use. Is it ok if we explore this? 
• Assess types and amounts of substances: What are you taking? How do you use it 
and how often? Are you using anything else? How much are you spending? 
• Is your partner or anybody else in the family also using substances? 
• What is your understanding of the impact of the substance use on you and your baby 
during pregnancy? 
• Are you booked with maternity services and receiving antenatal care? 
• Have you been referred to any other services such as a specialist addictions service? 
What are those services currently providing? 
• Who is supporting you during pregnancy and after birth? 
• Would you like to breastfeed? 
 
 
 
 
 
 
 
 
How this article was made 
We reviewed relevant UK guidelines and papers from our reference libraries, in addition 
to reference searches on key papers. Our recommendations are based on these 
evidence-based guidelines and the literature cited by them. 
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Box 2- Questions to ask in a brief intervention 
What is your understanding of how the substances that you are using may affect your 
pregnancy and baby?  
This may be followed by information giving about risks in an empathetic and non-
judgemental way. 
Have you thought about cutting down? 
This may be followed with discussion about perceived barriers to stopping or reducing 
substance use. 
Would you like more information about how we can support you with this? 
This may be followed by further information about options for support, with an emphasis on 
individual responsibility for decision making 
Always end by instilling hope that she is capable of change.  
Box 3- ICD-11 criteria for dependence18 
For any substance, three or more of the following should have been present together at 
some time during the previous year: 
• Strong desire or compulsion to take the substance. 
• Difficulty in controlling substance-taking behaviour, e.g. onset, termination or levels 
of use. 
• Physiological withdrawal state when substance use is stopped or reduced (symptoms 
vary depending on the substance); may also be associated with use of the substance 
(or a closely related one) to relieve or avoid the withdrawal symptoms.  
• Tolerance, whereby increased doses of the substance are required to achieve effects 
originally produced by lower doses. 
• Neglect of alternative pleasures or interests other than the substance. 
• Persistence of substance use despite knowledge of its potential harms.  
Box 4- Opioids in the perinatal period: key facts 
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• Use of opioids (street heroin and other prescribed and non-prescribed opiates) by 
the mother may lead to withdrawal in the fetus and/or overdose in the mother.46 
Other possible risks include those from injecting (such as infected injection sites and 
blood-borne viruses), the effects of co-morbid alcohol, benzodiazepine and stimulant 
use, poor diet and malnutrition, neglect of personal care, domestic violence and 
poor engagement with obstetric services.  
• Neonatal abstinence syndrome (NAS) occurs in between 70 and 95% of neonates 
exposed to opioids, including opioid substitute therapy (OST) during pregnancy.46 
Signs include a high-pitched cry, rapid breathing, ineffective sucking and excessive 
wakefulness.  
• Methadone or buprenorphine (as per standard protocols) are prescribed at a dose 
that stops or minimises illicit opioid use, with a focus on maintaining stability.7 
Methadone dosing may need to be increased in the third trimester of pregnancy as 
its metabolism increases.20 Consider split dosing to minimise fetal intoxication or 
withdrawal.47 The choice of buprenorphine versus methadone should be 
individualised to the patient and switching during pregnancy, particularly if well 
maintained, is discouraged.7 
• Generally avoid opioid detoxification during pregnancy; relapse rates are high and 
risks are greater from failed detoxification and relapse to illicit drug use than from 
opioid maintenance treatment.7 30 However, in particularly stable women who 
choose detoxification, the second trimester is recommended.20 
• Women may relapse after pregnancy. Warn them that they may have lost their 
tolerance and could overdose unexpectedly. 
• If a child of an opioid-using mother has been taken into care after birth, the woman 
may be more at risk of suicide.48 
• Opioid use, including methadone and buprenorphine, are not absolute 
contraindications to breastfeeding.20 
Box 5- Benzodiazepines in the perinatal period: key facts 
 
• Benzodiazepine use is often co-morbid with other substance use49 and may 
exacerbate the neonatal abstinence syndrome (NAS) associated with opioid use 
12 
 
during pregnancy. However, consider and enquire about benzodiazepine use 
(including prescribed benzodiazepines) in all pregnant women. 
• Evidence is conflicting regarding short- and long-term impacts of benzodiazepines on 
the developing infant.50-53  ‘Floppy baby syndrome’ (including poor muscle tone, 
hypothermia, lethargy and breathing and feeding difficulties) has been reported in 
neonates exposed to benzodiazepines in utero. Make women aware of these 
potential risks but such risks should be weighed against the necessity of their short-
term use in, for example, alcohol detoxification.7  
• WHO guidelines recommend gradual dose reduction using long-acting 
benzodiazepines at the lowest effective dose, for as long as is required to manage 
the symptoms of withdrawal. Gradual taper will reduce symptoms of withdrawal. 
Consider inpatient admission for benzodiazepine detoxification in pregnancy, given 
the risks of withdrawal such as seizures.7 
• Benzodiazepines are transferred into breast milk; there is less concern about 
breastfeeding when taken at normal prescribed doses but higher doses may lead to 
infant sedation, irritability and withdrawal. As ‘normal prescribed doses’ may vary 
internationally and guidelines do not specify, this advice should be applied with 
caution.7 
Box 6- Stimulants in the perinatal period: key facts 
• Stimulants such as cocaine, amphetamines and mephedrone are all potent 
vasoconstrictors that can affect the developing fetus at any gestation, leading to the 
obstetric complications of placental abruption and premature rupture of membranes 
and a potentially increased risk for congenital anomalies, low birth weight and 
preterm birth.54 55  Advise women using stimulants of these risks and encourage 
them to stop completely.  
• A neonatal withdrawal syndrome has been reported in some infants involving 
symptoms such as vomiting and restlessness.56 
• Consider inpatient care in the management of stimulant withdrawal during 
pregnancy.7 There are currently no clinically effective substitute or relapse 
prevention medications to treat stimulant dependence, making psychosocial 
interventions the mainstay of treatment.   
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• Women using stimulants should be advised not to breastfeed.7 
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